When a model proposes the molecule, who gets credit for the drug?

An MIT Technology Review feature dated 21 August 2026 examines the attribution fight opening up in AI-designed medicine, taking Insilico Medicine's claim that its generative platform discovered a pulmonary-fibrosis candidate as the test case for what a model can be said to have found.

What it means Credit decides patents, publications and funding, so the attribution convention set now will price the next decade of AI-assisted discovery.